Chemotherapy of disseminated testicular cancer. A random prospective study

Lawrence Einhorn, S. D. Williams

Research output: Contribution to journalArticle

174 Citations (Scopus)

Abstract

Seventy-eight patients with disseminated testicular cancer were entered on a random prospective study evaluating 3 separate remission induction arms. Therapy with cis-diamminedichloroplatinum (20 mg/M2 for 5 consecutive days every 3 weeks for 3-4 courses) and bleomycin (30 units intravenous push weekly for 12 consecutive wk) was constant. Patients were allocated at random to one of the following induction regimens (in combination with platinum plus bleomycin): (1) vinblastine 0.4 mg/kg every 3 weeks for 4 courses; (2) vinblastine 0.3 mg/kg every 3 weeks for four courses; or (3) vinblastine 0.2 mg/kg plus Adriamycin 50 mg/M2 every 3 weeks for 4 courses. All patients received maintenance therapy with vinblastine 0.3 mg/kg once a month for 20 months (total therapy two years) unless progressive disease intervened. The incidence of granulocytopenic fever and sepsis was highest with regimen 1, as 9 patients (35%) developed granulocytopenic fever requiring hospitalization and antibiotics; only 4 (15%) patients on regimen 2 developed granulocytopenic fever. No patients on regimen 2 had documented sepsis. Fifty-three patients (68%) achieved complete remission and an additional 11 patients were rendered free of disease with surgical resection of residual localized disease. Fifty-three patients (68%) remain alive and continuously free of disease from 15+ to 39+ mth. There was no difference in the complete remission rate of disease-free status with the higher dosage of vinblastine (regimen 1) during remission induction therapy compared to the less toxic lower dosage of vinblastine (regimen 2). This suggests that dosage reduction of vinblastine to 0.3 mg/kg can produce equivalent therapeutic results with diminished toxicity, and we no longer recommend the 0.4 mg/kg vinblastine dosage.

Original languageEnglish
Pages (from-to)1339-1344
Number of pages6
JournalCancer
Volume46
Issue number6
StatePublished - 1980

Fingerprint

Testicular Neoplasms
Vinblastine
Prospective Studies
Drug Therapy
Remission Induction
Fever
Bleomycin
Sepsis
Therapeutics
Poisons
Platinum
Doxorubicin
Cisplatin
Hospitalization
Anti-Bacterial Agents
Incidence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Chemotherapy of disseminated testicular cancer. A random prospective study. / Einhorn, Lawrence; Williams, S. D.

In: Cancer, Vol. 46, No. 6, 1980, p. 1339-1344.

Research output: Contribution to journalArticle

Einhorn, Lawrence ; Williams, S. D. / Chemotherapy of disseminated testicular cancer. A random prospective study. In: Cancer. 1980 ; Vol. 46, No. 6. pp. 1339-1344.
@article{75fb78adffec41a78c3b87515f81238d,
title = "Chemotherapy of disseminated testicular cancer. A random prospective study",
abstract = "Seventy-eight patients with disseminated testicular cancer were entered on a random prospective study evaluating 3 separate remission induction arms. Therapy with cis-diamminedichloroplatinum (20 mg/M2 for 5 consecutive days every 3 weeks for 3-4 courses) and bleomycin (30 units intravenous push weekly for 12 consecutive wk) was constant. Patients were allocated at random to one of the following induction regimens (in combination with platinum plus bleomycin): (1) vinblastine 0.4 mg/kg every 3 weeks for 4 courses; (2) vinblastine 0.3 mg/kg every 3 weeks for four courses; or (3) vinblastine 0.2 mg/kg plus Adriamycin 50 mg/M2 every 3 weeks for 4 courses. All patients received maintenance therapy with vinblastine 0.3 mg/kg once a month for 20 months (total therapy two years) unless progressive disease intervened. The incidence of granulocytopenic fever and sepsis was highest with regimen 1, as 9 patients (35{\%}) developed granulocytopenic fever requiring hospitalization and antibiotics; only 4 (15{\%}) patients on regimen 2 developed granulocytopenic fever. No patients on regimen 2 had documented sepsis. Fifty-three patients (68{\%}) achieved complete remission and an additional 11 patients were rendered free of disease with surgical resection of residual localized disease. Fifty-three patients (68{\%}) remain alive and continuously free of disease from 15+ to 39+ mth. There was no difference in the complete remission rate of disease-free status with the higher dosage of vinblastine (regimen 1) during remission induction therapy compared to the less toxic lower dosage of vinblastine (regimen 2). This suggests that dosage reduction of vinblastine to 0.3 mg/kg can produce equivalent therapeutic results with diminished toxicity, and we no longer recommend the 0.4 mg/kg vinblastine dosage.",
author = "Lawrence Einhorn and Williams, {S. D.}",
year = "1980",
language = "English",
volume = "46",
pages = "1339--1344",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Chemotherapy of disseminated testicular cancer. A random prospective study

AU - Einhorn, Lawrence

AU - Williams, S. D.

PY - 1980

Y1 - 1980

N2 - Seventy-eight patients with disseminated testicular cancer were entered on a random prospective study evaluating 3 separate remission induction arms. Therapy with cis-diamminedichloroplatinum (20 mg/M2 for 5 consecutive days every 3 weeks for 3-4 courses) and bleomycin (30 units intravenous push weekly for 12 consecutive wk) was constant. Patients were allocated at random to one of the following induction regimens (in combination with platinum plus bleomycin): (1) vinblastine 0.4 mg/kg every 3 weeks for 4 courses; (2) vinblastine 0.3 mg/kg every 3 weeks for four courses; or (3) vinblastine 0.2 mg/kg plus Adriamycin 50 mg/M2 every 3 weeks for 4 courses. All patients received maintenance therapy with vinblastine 0.3 mg/kg once a month for 20 months (total therapy two years) unless progressive disease intervened. The incidence of granulocytopenic fever and sepsis was highest with regimen 1, as 9 patients (35%) developed granulocytopenic fever requiring hospitalization and antibiotics; only 4 (15%) patients on regimen 2 developed granulocytopenic fever. No patients on regimen 2 had documented sepsis. Fifty-three patients (68%) achieved complete remission and an additional 11 patients were rendered free of disease with surgical resection of residual localized disease. Fifty-three patients (68%) remain alive and continuously free of disease from 15+ to 39+ mth. There was no difference in the complete remission rate of disease-free status with the higher dosage of vinblastine (regimen 1) during remission induction therapy compared to the less toxic lower dosage of vinblastine (regimen 2). This suggests that dosage reduction of vinblastine to 0.3 mg/kg can produce equivalent therapeutic results with diminished toxicity, and we no longer recommend the 0.4 mg/kg vinblastine dosage.

AB - Seventy-eight patients with disseminated testicular cancer were entered on a random prospective study evaluating 3 separate remission induction arms. Therapy with cis-diamminedichloroplatinum (20 mg/M2 for 5 consecutive days every 3 weeks for 3-4 courses) and bleomycin (30 units intravenous push weekly for 12 consecutive wk) was constant. Patients were allocated at random to one of the following induction regimens (in combination with platinum plus bleomycin): (1) vinblastine 0.4 mg/kg every 3 weeks for 4 courses; (2) vinblastine 0.3 mg/kg every 3 weeks for four courses; or (3) vinblastine 0.2 mg/kg plus Adriamycin 50 mg/M2 every 3 weeks for 4 courses. All patients received maintenance therapy with vinblastine 0.3 mg/kg once a month for 20 months (total therapy two years) unless progressive disease intervened. The incidence of granulocytopenic fever and sepsis was highest with regimen 1, as 9 patients (35%) developed granulocytopenic fever requiring hospitalization and antibiotics; only 4 (15%) patients on regimen 2 developed granulocytopenic fever. No patients on regimen 2 had documented sepsis. Fifty-three patients (68%) achieved complete remission and an additional 11 patients were rendered free of disease with surgical resection of residual localized disease. Fifty-three patients (68%) remain alive and continuously free of disease from 15+ to 39+ mth. There was no difference in the complete remission rate of disease-free status with the higher dosage of vinblastine (regimen 1) during remission induction therapy compared to the less toxic lower dosage of vinblastine (regimen 2). This suggests that dosage reduction of vinblastine to 0.3 mg/kg can produce equivalent therapeutic results with diminished toxicity, and we no longer recommend the 0.4 mg/kg vinblastine dosage.

UR - http://www.scopus.com/inward/record.url?scp=0019149002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019149002&partnerID=8YFLogxK

M3 - Article

VL - 46

SP - 1339

EP - 1344

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -